All In Biotech

Drugs by condition

Drugs approved for postpartum depression

Brand-name prescription drugs and biologics whose FDA label lists postpartum depression as an approved use. Matched on the label phrases: "postpartum depression".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

1

Still marketed, NDA or BLA

Drug classes

1

Novel drugs

1

New molecular entities and new biologics

In development

3

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for postpartum depression.

  • Zurzuvae (Zuranolone) · Biogen NovelPriority reviewAug 4, 2023

All approved drugs for postpartum depression, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator (1)

Drugs in development for postpartum depression

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • MI078Phase 32 trials

    Nanjing Minova Pharmaceutical Co., Ltd. · Postpartum Depression (PPD), Postpartum Depression

  • RE104Phase 23 trials

    Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression

  • NORA520Phase 21 trial

    TWi Biotechnology, Inc. · Depression, Postpartum, Postpartum Depression, Post-partum Depression

More on postpartum depression: recruiting trials · published research

Related in psychiatry: Depression (major depressive disorder) · Schizophrenia · Bipolar disorder · ADHD · Anxiety disorders · Insomnia · Opioid use disorder · Alcohol dependence · Smoking cessation · PTSD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.